TY - JOUR
T1 - A randomized, masked, cross-over trial of lisinopril for inflammatory macular edema
AU - Van Kooij, Bram
AU - Fijnheer, Rob
AU - De Boer, Joke
AU - Ten Dam-Van Loon, Ninette
AU - Bartelink, Imke
AU - Roest, Mark
AU - Rothova, Aniki
N1 - Funding Information:
This study was supported in part by the Dr F. P. Fischer Foundation, Utrecht, The Netherlands. The Dr F. P. Fischer Foundation is a nonprofit organization and had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; and the preparation, review, or approval of the manuscript.
Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2006/4
Y1 - 2006/4
N2 - • PURPOSE: To analyze the effect of angiotensin-converting enzyme (ACE) inhibitor lisinopril on inflammatory cystoid macular edema and visual acuity. • DESIGN: Randomized, double-blind, placebo-controlled cross-over trial. • METHODS: setting: Outpatient clinic of the Department of Ophthalmology at the University Medical Center of Utrecht. Patients: Forty patients with inflammatory cystoid macular edema were included. intervention: Each patient received lisinopril (10 mg daily) or placebo for three months. After two months of a lisinopril/placebo free wash-out period, the groups received the reverse study medication for three months. Fluorescein angiography was performed to evaluate the retina. main outcome measures: Cystoid macular edema, best-corrected visual acuity and contrast sensitivity. • RESULTS: Lisinopril had no effect on cystoid macular edema, visual acuity, papillary leakage, retinal vasculitis, and choroidal leakage. In a subgroup analysis, we observed a decrease in blood pressure (lisinopril, 14 of 36 patients; placebo, 5 of 36 patients; P = .02) and a decrease in morning urinary albumin excretion (lisinopril, 23 of 35 patients; placebo 10 of 34 patients, P = .003) was observed. • CONCLUSIONS: Although lisinopril had no effect on inflammatory cystoid macular edema and visual acuity, we found a positive effect on the vascular system.
AB - • PURPOSE: To analyze the effect of angiotensin-converting enzyme (ACE) inhibitor lisinopril on inflammatory cystoid macular edema and visual acuity. • DESIGN: Randomized, double-blind, placebo-controlled cross-over trial. • METHODS: setting: Outpatient clinic of the Department of Ophthalmology at the University Medical Center of Utrecht. Patients: Forty patients with inflammatory cystoid macular edema were included. intervention: Each patient received lisinopril (10 mg daily) or placebo for three months. After two months of a lisinopril/placebo free wash-out period, the groups received the reverse study medication for three months. Fluorescein angiography was performed to evaluate the retina. main outcome measures: Cystoid macular edema, best-corrected visual acuity and contrast sensitivity. • RESULTS: Lisinopril had no effect on cystoid macular edema, visual acuity, papillary leakage, retinal vasculitis, and choroidal leakage. In a subgroup analysis, we observed a decrease in blood pressure (lisinopril, 14 of 36 patients; placebo, 5 of 36 patients; P = .02) and a decrease in morning urinary albumin excretion (lisinopril, 23 of 35 patients; placebo 10 of 34 patients, P = .003) was observed. • CONCLUSIONS: Although lisinopril had no effect on inflammatory cystoid macular edema and visual acuity, we found a positive effect on the vascular system.
UR - http://www.scopus.com/inward/record.url?scp=33645308286&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2005.11.056
DO - 10.1016/j.ajo.2005.11.056
M3 - Article
C2 - 16564798
AN - SCOPUS:33645308286
VL - 141
SP - 646
EP - 651
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
SN - 0002-9394
IS - 4
ER -